{
    "nct_id": "NCT05147350",
    "official_title": "Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with FOLFIRI for the Treatment of Advanced Solid Tumors",
    "inclusion_criteria": "* Male or female and ≥18 years-of-age at the time of signature of the informed consent\n* Confirmed advanced solid tumors resistant or refractory to standard treatment\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* All patients must have locally advanced or metastatic CRC, GI, or esophageal cancer(s) and radiographic evidence of progressing disease.\n* Measurable disease as per RECIST v1.1\n* Submission of available tumor tissue or willingness to have a biopsy performed if safe and feasible\n* Acceptable hematologic and organ function at screening\n* Negative pregnancy test for women of childbearing potential at Screening and prior to first study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to swallow and retain oral medications.\n* Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half- lives, whichever is shorter, prior to first dose of study treatment.\n* History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.\n* Patients who are pregnant or breastfeeding\n* Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.\n* Major surgery within 4 weeks prior to first study treatment dose.\n* Uncontrolled, symptomatic brain metastases.\n* Uncontrolled high blood pressure\n* Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.\n* Moderate or severe hepatic impairment\n* Cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥Class 2\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.",
    "miscellaneous_criteria": ""
}